As much as 75% of overweight and obese individuals have steatotic liver disease, according to results of a recent cross-sectional, observational study.
In addition, the study further delved into subcategories of steatotic liver disease (SLD), finding that in this population, the prevalences of metabolic dysfunction–associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and mixed metabolic dysfunction and ALD were 67.3%, 2.6% and 4.8%, respectively. The